KALA BIO (NASDAQ:KALA – Get Free Report) and UroGen Pharma (NASDAQ:URGN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for KALA BIO and UroGen Pharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KALA BIO | 0 | 0 | 2 | 0 | 3.00 |
| UroGen Pharma | 0 | 0 | 3 | 0 | 3.00 |
KALA BIO currently has a consensus target price of $16.50, indicating a potential upside of 169.61%. UroGen Pharma has a consensus target price of $51.17, indicating a potential upside of 242.60%. Given UroGen Pharma’s higher possible upside, analysts clearly believe UroGen Pharma is more favorable than KALA BIO.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KALA BIO | $3.89 million | 4.43 | -$42.20 million | ($15.15) | -0.40 |
| UroGen Pharma | $82.71 million | 4.23 | -$102.24 million | ($3.40) | -4.39 |
KALA BIO has higher earnings, but lower revenue than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
24.6% of KALA BIO shares are held by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are held by institutional investors. 13.4% of KALA BIO shares are held by insiders. Comparatively, 5.1% of UroGen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares KALA BIO and UroGen Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KALA BIO | N/A | -366.43% | -66.41% |
| UroGen Pharma | -123.74% | N/A | -62.48% |
Volatility and Risk
KALA BIO has a beta of -2.03, suggesting that its stock price is 303% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Summary
UroGen Pharma beats KALA BIO on 8 of the 13 factors compared between the two stocks.
About KALA BIO
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
About UroGen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.
